Glixogen Therapeutics is a biopharmaceutical company developing a treatment to enhance remyelination in neurodegenerative disorders that are driven by damage to the neuron's myelin sheath, such as multiple sclerosis (MS).
Glixogen Therapeutics has discovered selective small molecule inhibitors of the transcription factor Gli1, a novel target that facilitates neuronal remyelination towards modifying the outcome of the disease.
Glixogen Therapeutics was founded at the FutuRx biotechnology incubator.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Glixogen Therapeutics Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Jan 14, 2019
www.prweb.com
FutuRx Launches GliXogen Therapeutics to Develop Novel Therapies for Multiple Sclerosis and Other Demyelinating Disorders